CoChat

Hepcidin-25 is a Marker of the Response Rather than Resistance to Exogenous Erythropoietin in Chronic Kidney Disease/Chronic Heart Failure Patients

van der Putten, Karien, Jie, Kim E., van den Broek, Daan, Kraaijenhagen, Rob J., Laarakkers, Coby, Swinkels, Dorine W., Braam, Branko, Gaillard, Carlo A. · 2010 · European Journal of Heart Failure
Cited by 82

The DOI matches its Crossref record; 6 of the 6 references it cites were found in a registry or an index.

Abstract

Aims: Erythropoietin (EPO) resistance, an important cause of anaemia in patients with heart and renal failure, is associated with increased mortality. The hypothesis of the present study was that exogenous EPO decreases hepcidin levels and that the decrease in hepcidin levels upon EPO treatment is related to the bone marrow response. Methods and results: In the EPOCARES trial, patients with renal failure (glomerular filtration rate 20–70 mL/min), heart failure, and anaemia were randomized to receive 50 IU/kg/week EPO (n = 20) or not (n = 13). Haemoglobin (Hb), hepcidin-25, ferritin, reticulocytes, serum transferrin receptor (sTfR), IL-6, and high-sensitivity C-reactive protein were measured at baseline and during treatment. Hepcidin-25 was measured by weak cation exchange chromatography/matrix assisted laser desorption ionization time-of-flight mass spectrometry. Baseline hepcidin levels were increased compared with a healthy reference population and were inversely correlated with Hb (r2 = 0.18, P = 0.02), and positively with ferritin (r2 = 0.51, P < 0.001), but not with renal function, high-sensitivity C-reactive protein or IL-6. Erythropoietin treatment increased reticulocytes (P < 0.001) and sTfR (P < 0.001), and decreased hepcidin (P < 0.001). Baseline hepcidin levels and the magnitude of the decrease in hepcidin correlated with the increase in reticulocytes (r2 = 0.23, P = 0.03) and sTfR (r2 = 0.23, P = 0.03) and also with the Hb response after 6 months (r2 = 0.49, P = 0.001). Conclusion: In this group of patients with combined heart and renal failure and anaemia, increased hepcidin levels were associated with markers of iron load and not with markers of inflammation. The (change in) hepcidin levels predicted early and long-term bone marrow response to exogenous EPO. In our group hepcidin seems to reflect iron load and response to EPO rather than inflammation and EPO resistance.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1093/eurjhf/hfq099

Cites

6 of 6 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 6 references

Cited by

See all 82

Metadata

Authors
van der Putten, K., Jie, K. E., van den Broek, D., Kraaijenhagen, R. J., Laarakkers, C., Swinkels, D. W., Braam, B., & Gaillard, C. A.
Venue
European Journal of Heart Failure
Published
2010-09-01
Volume
12
Issue
9
Pages
943-950
ISSN
  • 1388-9842 (ISSN-L)
  • 1879-0844
OpenAlex
W2003478281
Cited by
82
References
6
FWCI
4.67
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Hepcidin-25 is a Marker of the Response Rather than Resistance to Exogenous Erythropoietin in Chronic Kidney Disease/Chronic Heart Failure Patients. https://app.cochat.ai/papers/10.1093/eurjhf/hfq099
The paper
van der Putten, K., Jie, K. E., van den Broek, D., Kraaijenhagen, R. J., Laarakkers, C., Swinkels, D. W., Braam, B., & Gaillard, C. A. (2010). Hepcidin-25 is a Marker of the Response Rather than Resistance to Exogenous Erythropoietin in Chronic Kidney Disease/Chronic Heart Failure Patients. European Journal of Heart Failure. https://doi.org/10.1093/eurjhf/hfq099

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.